Impact of Neoadjuvant Immunotherapy on Perioperative Outcomes in Esophageal Adenocarcinoma

Patients with locally advanced esophageal adenocarcinoma who received neoadjuvant immunotherapy (io) combined with chemotherapy showed similar perioperative outcomes compared to those who received neoadjuvant chemotherapy alone. Rates of overall and major complications, anastomotic leak, respiratory complications, hospital stay length, and mortality were comparable between the two groups. The addition of immunotherapy did not significantly alter short-term outcomes after esophagectomy.